Browse recruiting and upcoming clinical trials for thrombotic thrombocytopenic purpura.
Patient-friendly, AI-assisted summaries based on official ClinicalTrials.gov ↗ records. Last updated: Oct 10, 2026
About this listHide
ClinicalTrials.gov is the complete and most up-to-date source. Trials may be missing, and trial information may have changed since our last check. Always verify important information in the official registry.
Who can join AIAdults 18–65 with multiple refractory autoimmune diseases such as SLE, Sjögren, systemic sclerosis, ANCA‑vasculitis, inflammatory myopathy, Behçet, IgG4‑RD, antiphospholipid syndrome, or TTP.
What is being studied AITests BCMA-CD19 CAR-T cell therapy for multiple refractory autoimmune diseases.
Who can join AIPeople with immune-mediated thrombotic thrombocytopenic purpura (iTTP), a form of thrombotic microangiopathy, who meet clinical/lab entry criteria.
What is being studied AITests a PEX-free regimen using plasma infusions, caplacizumab and immunosuppression for iTTP.
Who can join AIPeople with confirmed or suspected hereditary (congenital) thrombotic thrombocytopenic purpura (Upshaw‑Schulman) and their family members.
What is being studied AICollects clinical, genetic, and treatment data on hereditary TTP patients and family members.
Who can join AIPeople diagnosed with thrombosis and hemostasis diseases (examples: ITP, TTP, hereditary or acquired hemophilia, DIC, thrombophilia, DVT, PE, and related disorders).
What is being studied AICollects medical records, questionnaires, and follow-up data on thrombosis and bleeding disorders.